Article
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Cancer chemotherapy and pharmacology - 1 Oct 2015
Kuwako Tomohito, Imai Hisao, Masuda Tomomi, Miura Yosuke, Seki Kaori, Yoshino Reiko, Kaira Kyoichi, Utsugi Mitsuyoshi, Shimizu Kimihiro, Sunaga Noriaki, Tomizawa Yoshio, Ishihara Shinichi, Ishizuka Takao, Mogi Akira, Hisada Takeshi, Minato Koichi, Takise Atsushi, Saito Ryusei, Yamada Masanobu
Abstract excerpt
PURPOSE: The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR mutation has not been elucidated. Therefore, the objective of this study was to investigate the efficacy and feasibility of gefitinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.